Researcher: Birtaş Ateşoğlu, Elif
Loading...
Name Variants
Birtaş Ateşoğlu, Elif
Email Address
Birth Date
5 results
Search Results
Now showing 1 - 5 of 5
Publication Metadata only Programmed cell death ligand 1 expression level and prognostic significance in acute myeloid leukemia(Springer India, 2022) Geduk, Ayfer; Mehtap, Ozgur; Demirsoy, Esra T.; Menguc, Meral U.; Tarkun, Pinar; Hacihanefioglu, Abdullah; Balci, Sibel; N/A; Birtaş Ateşoğlu, Elif; Doctor; N/A; Koc University Hospital; N/APurpose: We aimed to evaluate the expression level of programmed death ligand-1 (PD-L1) and its effects on prognosis in acute myeloid leukemia. Methods: The flow cytometry was used to detect PD-L1 expression on leukemic cells of 86 de novo acute myeloid leukemia patients with longitudinal follow-up. Results: Median follow-up was 13 (0-73) months. The mean of expression level was 3.22 +/- 0.47 at diagnosis and ranged from 0 to 28%. PD-L1 expression tended to be lower in patients with acute promyelocytic leukemia (2.47 +/- 1.08, p = 0.09) but there was no significant difference between neither diagnostic nor cytogenetic subgroups. There was no difference in PD-L1 levels between the patients who achieved complete remission (3.4 +/- 0.61) and those who did not (2.91 +/- 0.72, p = 0.94). The patients with low PD-L1 at diagnosis (median 25 mo [95% CI; 0-56.7]) had a longer overall survival compared with high PD-L1 (median 13 mo [95% CI; 5.52-25.17], p = 0.079). PD-L1 expression was lower at relapse (2.04 +/- 0.79) compared to initial diagnosis (4.52 +/- 0.93, p = 0.049). The patients who had overall survival longer than 1 year showed lower PD-L1 expression at relapse (0.66 +/- 0.93) compared with who had not (5.06 +/- 4.28, p = 0.052). A negative correlation between CD33 and PD-L1 (r = - 0.303, p = 0.005) was detected. Conclusion: Despite its low expression levels, PD-L1 appears to be a clinically important prognostic factor. The negative correlation determined between PD-L1 and CD33 supports the combination approach of PD-L1 inhibitors and CD33 targeted immunotherapies.Publication Metadata only Comparative efficacy and safety of Beam and Team conditioning regimens for autologous stem cell transplantation in lymphoma patients(Elsevier, 2023) Deveci, Burak; Bayrak, Esra; Kublashvili, George; Toptas, Tayfur; Saba, Rabin; Gulbas, Zafer; N/A; Birtaş Ateşoğlu, Elif; Doctor; N/A; Koç University Hospital; N/ABackground. Conditioning regimens with high-dose chemotherapy and autologous stem cell transplantation (ASCT) are the mainstays of treatment in lymphoma patients. Although the most frequently used conditioning regimen is the BEAM regimen (Carmustine, Etoposide, Cytarabine, and Melphalan), and alternatives are also used in certain circumstances. The TEAM regimen (carmustine is substituted by the alkylating agent thiotepa) is one of these alternatives; however, data regarding the comparisons of efficacy and safety profiles of these 2 regimens is scarce. This study compared the outcomes of patients who received conditioning regimens with BEAM and TEAM and underwent an ASCT.Methods. This study was conducted as a retrospective assessment of 294 patient outcomes in terms of efficacy and safety. Adult patients with lymphoma diagnosis who received BEAM or TEAM conditioning regimens and underwent an ASCT between January 1, 2016 and December 31, 2019 were included in the analyses.Results. A total of 294 patients (median age at ASCT: 50 years, males: 60.5%, diffuse large B-cell lymphoma: 35%) were included. Eighty patients (27.2%) received the TEAM regimen, and 214 (72.8%) received the BEAM regimen. Regarding safety profiles, the thrombocyte engraft-ment time was significantly higher in the TEAM group (P = .003) and fever of unknown etiology was significantly higher in the BEAM group (P = .042). Also, nausea was more in the TEAM group (P = .031). The complete remission rate was 57.5% and 70.3% in the TEAM and BEAM regimens, respectively. The overall mortality rate was 37.3% and not significantly different between the groups (43% and 35% in the TEAM and BEAM groups, P = .22) over a similar median follow-up of 1667 days (P = .28). The 3-year survival rate was 66% and 67% and the 5-year survival rate was 52% and 58% in the TEAM and BEAM regimens, respectively, without significant difference.Conclusion. To the best of our knowledge, this is one of the few studies in the literature that compared the TEAM and BEAM as conditioning regimens for ASCT in lymphoma patients. The 2 regimens may provide similar overall survival outcomes and have a comparable safety pro-file. Although the BEAM regimen may be associated with longer progression-free survival times, the difference may be covered by the similar survival after ASCT.Publication Metadata only Trastuzumab deruxtecan in her2-low breast cancer(Massachusetts Medical Soc, 2022) Özbalak, Murat; N/A; Ferhanoğlu, Ahmet Burhan; Birtaş Ateşoğlu, Elif; Faculty Member; N/A; School of Medicine; School of Medicine; 18320; N/AN/APublication Metadata only Glofitamab in relapsed/refractory Diffuse Large B Cell Lymphoma: real world data(American Society of Hematology (ASH), 2022) Gulbas, Zafer; Uzay, Ant; Ozcan, Muhit; Ozkalemkas, Fahir; Dal, Mehmet Sinan; Deveci, Burak; Bekoz, Huseyin; Sevindik, Omur Gokmen; Toptas, Tayfur; Yilmaz, Asu Fergun; Koyun, Derya; Alkis, Nihan; N/A; Ferhanoğlu, Ahmet Burhan; Kalyon, Hakan; Akay, Olga Meltem; Birtaş Ateşoğlu, Elif; Faculty Member; Researcher; Faculty Member; Doctor; School of Medicine; School of Medicine; School of Medicine; N/A; Koç University Hospital; 18320; 175363; 170966; N/AN/APublication Metadata only Treatment of mantle-cell lymphoma(NLM (Medline), 2022) Ozbalak, Murat; Ferhanoğlu, Ahmet Burhan; Birtaş Ateşoğlu, Elif; Faculty Member; Doctor; School of Medicine; Koç University Hospital; 18320; N/AN/A